<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636464</url>
  </required_header>
  <id_info>
    <org_study_id>A-2017-010</org_study_id>
    <nct_id>NCT03636464</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Antibiotics in Patients Undergoing Renal Replacement Therapies</brief_title>
  <acronym>RRTdose</acronym>
  <official_title>Pharmacokinetics and Deposition of Commonly Prescribed Antibiotics in Hospitalized Critically Ill Patients Undergoing Renal Replacement Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cleveland Clinic Abu Dhabi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of the Sciences in Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cleveland Clinic Abu Dhabi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aiming to describe the pharmacokinetic and pharmacodynamic profile of
      intravenous meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam ,
      Ceftolozane/Tazobactam , and piperacillin/tazobactam in the plasma and determine how much is
      removed by Renal Replacement Therapies to ensure adequate dosing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pharmacokinetic evaluation and clinical outcomes will be an open-label study of 12-16
      adult patients/antibiotic dose/modality to a total number of 180-240 patients, admitted to
      the acute care levels or intensive care unit at Cleveland Clinic Abu Dhabi receiving RRT and
      prescribed these seven antibiotics as recommended by their treating physicians. The
      collection of blood, ultrafiltrate or effluent fluids depending on RRT modality (HD or CRRT),
      and urine samples will begin after participants are administered first dose to determine if a
      loading dose will be required then after at least three doses (as prescribed by the treating
      physician) once these drugs will be at steady-state concentration. The study intervention
      duration will depend on dialysis modality expected to be 3 to 5 days depending on RRT
      modality and patients will be followed for outcomes (death or cure). Collected blood,
      effluent and urine samples will be assayed for drug concentration. The concentration data
      will be modeled by a computer program to determine the pharmacokinetic parameters used to
      predict future dosing in the case of RRT. Linear/logistic regression will be used as a
      component of statistical analysis to model the relationship between CRRT machine settings and
      the amount of the study drugs that will be removed by the filter. Information related to
      adverse events , clinical and microbiological cure will be collected in case report forms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum antibiotic concentrations over time during dose interval</measure>
    <time_frame>24 months</time_frame>
    <description>Blood will be collected at designated time points, serum samples will be assayed for drug concentration over time to describe pharmacokinetic disposition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of antibiotic removed by dialysis</measure>
    <time_frame>24 months</time_frame>
    <description>Dialysate will be collected and assayed for drug concentration to determine the amount of drug cleared by RRT with respect to different dialysis modalities and membranes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above minimum inhibitory concentration (T/MIC) for time dependent antibiotics</measure>
    <time_frame>24 months</time_frame>
    <description>Concentration/time data will be modeled mathematically (population pharmacokinetics and Monte Carlo simulation) to identify adequate dosing in this patient population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under concentration time curve over minimum inhibitory concentration for (Cmax/MIC) for concentration dependent antibiotics</measure>
    <time_frame>24 months</time_frame>
    <description>Concentration/time data will be modeled mathematically (population pharmacokinetics and Monte Carlo simulation) to identify adequate dosing in this patient population</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Renal Replacement Therapy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Pharmacokinetics</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients on renal replacement therapy, prescribed antibiotics in the regular course of care
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt; 18 year old

          -  Prescribed meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam ,
             Ceftolozane/Tazobactam , or piperacillin/tazobactam for treatment of infection as part
             of standard medical care

          -  Administered meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam ,
             Ceftolozane/Tazobactam ,or piperacillin/tazobactam while on renal replacement therapy
             (IHD or CRRT) or renal replacement therapy started while on any of these antibiotics

          -  Patients with hemoglobin &gt; 70 g/L without blood transfusion in the past 24 hours

          -  Informed consent given by patient, next of kin or legally authorized representative

        Exclusion Criteria:

          -  Less than 18 years of age

          -  Pregnant females

          -  Body mass index &lt; 18 or &gt; 35 kg/m2

          -  Presence of anemia (defined as hemoglobin &lt; 70 g/L), thrombocytopenia, or leukopenia
             as defined by hematocrit, platelet, or white blood cell count &lt; 75% of the lower limit
             of normal

          -  Concomitant receipt of another cephalosporin interfering with assay

          -  Participants likely to require surgical interventions during the study period if the
             surgery would interfere with dosing intervals or affect sampling process

          -  Protected patients; prisoners, patients with HIV, patients with physical or mental
             disabilities, psychiatric patients.

          -  Patients with documented life-threatening allergy (i.e anaphylaxis, angioedema) to any
             of the study drugs or their class.

          -  Patients with conditions known to significantly affect PK; (i.e. severe burn,
             significant ascites, spinal cord injury and cystic fibrosis)

          -  Any other reason felt by the investigators to potentially affect the outcomes of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wasim El Nekidy, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Abu Dhabi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Islam Ghazi, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wasim El Nekidy, PharmD</last_name>
    <phone>+971 2 6590200</phone>
    <phone_ext>47969</phone_ext>
    <email>ElnekiW@ClevelandClinicAbuDhabi.ae</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Islam Ghazi, PharmD</last_name>
    <phone>+12152688908</phone>
    <email>i.ghazi@usciences.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Abu Dhabi</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wasim S El Nekidy, PharmD</last_name>
      <phone>+97125092000</phone>
      <phone_ext>47969</phone_ext>
      <email>elnekiw@ccaduae.ae</email>
    </contact>
    <investigator>
      <last_name>Wasim El Nekidy, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Islam Ghazi, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cleveland Clinic Abu Dhabi</investigator_affiliation>
    <investigator_full_name>Wasim El Nekidy</investigator_full_name>
    <investigator_title>Senior Pharmacotherapy Specialist</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>antibiotics</keyword>
  <keyword>RRT</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

